The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.

The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.

Tingting Qiu, Yitong Wang, Shuyao Liang, Ru Han, Mondher Toumi

Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy (CGT) industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. As decision-makers shifted their priorities to COVID-19-related issues, the challenges in market authorisation, and price and reimbursement of CGTs were amplified. Nevertheless, it is encouraging to see that some CGT developers are adapting their efforts toward the development of promising COVID-19-related therapeutics and vaccines. Manufacturing resilience, digitalisation, telemedicine, value-based pricing, and innovative payment mechanisms will be increasingly harnessed to ensure that market access of CGTs is not severely disrupted.

2021

covid-19, regulatory, health technology assessment, Cell and gene therapies

10.1016/j.drudis.2021.04.020

Drug discovery today